Literature DB >> 26306743

Mitigative Effects of a Combination of Multiple Pharmaceutical Drugs on the Survival of Mice Exposed to Lethal Ionizing Radiation.

Tokuhisa Hirouchi, Koichi Ito, Manabu Nakano, Satoru Monzen, Hironori Yoshino, Mitsuru Chiba, Masaharu Hazawa, Akira Nakano, Junya Ishikawa, Masaru Yamaguchi, Kimio Tanaka, Ikuo Kashiwakura1.   

Abstract

It is important to establish an easy-to-use therapeutic protocol for the emergency medical care of patients involved in radiation accidents to reduce the radiation-related casualties. The present study aimed to establish an optimum therapeutic protocol using currently approved pharmaceutical drugs to increase the survival of victims exposed to lethal radiation. Different combinations of four drugs-recombinant human erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), c-mpl receptor agonist romiplostim (RP) and nandrolone decanoate (ND)-were administered to mice within 2 h after exposure to a lethal 7 Gy dose of γ-irradiation. On day 30 after irradiation, the condition of the mice was analyzed using various hematological parameters, such as the number of peripheral blood cells, bone marrow cells, hematopoietic progenitor cells and the expression of cell surface antigens. Approximately 10% of the untreated irradiated control mice survived for 21 days, but all of the control mice died by day 30. The combined administration of G-CSF, EPO and RP for five days immediately after irradiation led to a complete survival of the irradiated mice until day 30. However, the treatment with G-CSF, EPO and RP with ND led to only 75% survival at day 30. The hematological analyses showed that the numbers of almost all of hematopoietic cells in the surviving mice treated with effective medications recovered to the levels of non-irradiated mice. The present findings show that the combination of G-CSF, EPO and RP may be a useful countermeasure for victims exposed to accidental lethal irradiation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26306743     DOI: 10.2174/1389201016666150826125331

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  10 in total

Review 1.  Nuclear and Radiological Emergencies: Biological Effects, Countermeasures and Biodosimetry.

Authors:  Elena Obrador; Rosario Salvador-Palmer; Juan I Villaescusa; Eduardo Gallego; Blanca Pellicer; José M Estrela; Alegría Montoro
Journal:  Antioxidants (Basel)       Date:  2022-05-31

2.  Human Peripheral Blood Mononucleocyte Derived Myeloid Committed Progenitor Cells Mitigate H-ARS by Exosomal Paracrine Signal.

Authors:  Rishi Man Chugh; Payel Bhanja; Ximena Diaz Olea; Fang Tao; Kealan Schroeder; Ryan Zitter; Tanu Arora; Harsh Pathak; Bruce F Kimler; Andrew K Godwin; John M Perry; Subhrajit Saha
Journal:  Int J Mol Sci       Date:  2022-05-14       Impact factor: 6.208

3.  Serum miR-375-3p increase in mice exposed to a high dose of ionizing radiation.

Authors:  Mitsuru Chiba; Satoru Monzen; Chihiro Iwaya; Yuri Kashiwagi; Sunao Yamada; Yoichiro Hosokawa; Yasushi Mariya; Toshiya Nakamura; Andrzej Wojcik
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

Review 4.  Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Authors:  Michal Hofer; Zuzana Hoferová; Martin Falk
Journal:  Int J Mol Sci       Date:  2017-06-28       Impact factor: 5.923

5.  Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome.

Authors:  Masaru Yamaguchi; Marino Suzuki; Moeri Funaba; Akane Chiba; Ikuo Kashiwakura
Journal:  Stem Cell Res Ther       Date:  2020-08-03       Impact factor: 6.832

Review 6.  Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review.

Authors:  Michal Hofer; Zuzana Hoferová; Daniel Depeš; Martin Falk
Journal:  Molecules       Date:  2017-05-19       Impact factor: 4.411

7.  An Analysis of the Serum Metabolomic Profile for the Radiomitigative Effect of the Thrombopoietin Receptor Agonist Romiplostim in Lethally Whole-Body-Irradiated Mice.

Authors:  Yoshiaki Sato; Masaru Yamaguchi; Ikuo Kashiwakura
Journal:  Metabolites       Date:  2022-02-08

Review 8.  Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.

Authors:  Vijay K Singh; Thomas M Seed
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

Review 9.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

10.  The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation.

Authors:  Masaru Yamaguchi; Tokuhisa Hirouchi; Koki Yokoyama; Ayaka Nishiyama; Sho Murakami; Ikuo Kashiwakura
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.